In this interview, Eric Adams, chief executive officer of InMed Pharmaceuticals provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids.
InMed Pharmaceuticals (TSX: IN) is a Canada-based biopharmaceutical company focused on manufacturing and developing cannabinoids. Its biosynthesis platform has the potential to produce cannabinoids at a lower cost and with improved purity compared to currently used methods. The company is also developing a proprietary pipeline, including INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.
